

the sample were then prepared and subjected to electrophoresis using 12% (w/v) SDS-polyacrylamide gels. Proteins were transferred from the gels to 0.45 μ m PVDF membranes (Immobilon-P, Millipore Corp., Billerica, USA), and non-specific binding sites on the membranes were then blocked by overnight incubation in buffer containing dried milk and Tween 20. The blocked membranes were incubated with monoclonal antibody 3F4, washed extensively, and then incubated with a secondary horseradish peroxidase (HRP)-conjugated anti-mouse antibody (Sigma-Aldrich Corp.). After further extensive washing, bound antibody was detected using an ECL-Plus detection system (GE Healthcare UK Ltd, Buckinghamshire, UK) and exposure to blue-light sensitive film.

The level of PrP^{Sc} present in each sample was calculated based on the end-point dilution after analysis by WB. The end-point dilution for each titration was taken as the first dilution at which the 28 kDa PrP^{Sc} protein could not be detected. The reciprocal of this dilution was then taken as the titer of the agent, and expressed in arbitrary units/ml.

2.2.2. Method 2 (WB2)

WB was performed essentially as described by Lee et al. [14]. Briefly, samples were digested with proteinase K at approximately 6 U/ml for 60 min at 37 °C and centrifuged at approximately 20,000 \times g for 60 min at 4 °C. The pellet was then resuspended and denatured in a 1:1 mix of supernatant and sample buffer (62.5 mM Tris-HCl, pH 6.8, 10% (v/v) glycerol, 2% (w/v) SDS and 0.0025% (w/v) bromophenol blue, Invitrogen Corp. Carlsbad, USA), by heating at approximately 100 °C. Serial 3.2-fold (0.5 log₁₀) dilutions of the sample were prepared, and loaded onto 12% (w/v) SDS-polyacrylamide gels. Following electrophoresis, proteins were transferred to nitrocellulose membranes (Invitrogen Corp.), and the membranes blocked using buffer containing dried milk and Tween 20 for 1–2 h at room temperature. The blocked membranes were then incubated with monoclonal antibody 3F4, washed extensively, and incubated with a secondary alkaline phosphatase (AP)-conjugated anti-mouse antibody (Cambridge Biosciences Ltd., Cambridge, UK). After further extensive washing, bound antibody was detected using a CDP Star/Nitroblock II detection system (Applied Biosciences, Bedford, USA) and exposure to blue-light sensitive film.

The titer of PrP^{Sc} present in each sample was calculated slightly differently from WB1 and WB3. The end-point dilution for each titration was taken as the last dilution at which the 28 kDa PrP^{Sc} protein could be detected. The reciprocal of this dilution was then taken as the amount of agent in the sample volume tested, and was adjusted for the volume tested and any concentration factors, to give a titer/ml for the original process sample.

2.2.3. Method 3 (WB3)

Samples were ultracentrifuged twice at 150,000 \times g for 1 h. The samples in the precipitates were then resuspended in PBS at 1/1 or 1/10th volume of the original. Resuspended samples were treated with proteinase K at a final concentration of 10–100 μ g/ml. After incubation at 37 °C for 60 min, samples

were treated with 10 mM 4-(2-aminoethyl)-benzene sulfonyl fluoride hydrochloride (AEBSF) at room temperature for 10 min, then mixed with 5 \times SDS-polyacrylamide gel electrophoresis (PAGE) sample buffer (300 mM Tris-HCl, 12% (w/v) SDS, 25% (v/v) glycerol, and 0.025% (w/v) bromophenol blue, pH 6.8, with 25% (v/v) β -mercaptoethanol) and heated at 100 °C for 5 min. Samples were serially 5-fold diluted with 1 \times PAGE dilution buffer (60 mM Tris-HCl, 2.4% (w/v) SDS, 5% (v/v) glycerol, and 0.005% (w/v) bromophenol blue, pH 6.8). SDS-PAGE was performed at 30 mA per gel for approximately 42 min. The proteins in the gel were transferred to 0.45 μ m PVDF membranes. After treating with blocking buffer (5.0% (w/v) skimmed milk in PBS, 0.05% (v/v) Tween 20), the membrane was incubated with monoclonal antibody 3F4 at 4 °C overnight, then incubated with HRP-conjugated sheep anti-mouse IgG (Sigma-Aldrich Corp.). Bound antibody was visualized by chemiluminescence (ECL-Plus) on X-ray film. The titer of PrP^{Sc} present in the samples was calculated as described for method 1 in Section 2.2.1.

2.3. Evaluation of PrP^{Sc} removal by filtration

A 10% (v/v) concentration of "super-sonicated" 263K MF was prepared in PBS, and 10 ml aliquots were then filtered through a 220 nm or a 100 nm 4 cm² PVDF filter (Millex-GV or -VV, Millipore Corp.). In addition, 25 ml aliquots of "super-sonicated" 263K MF in PBS were filtered through a 0.01 m² P-75N (72 \pm 2 nm), P-35N (35 \pm 2 nm), or P-15N (15 \pm 2 nm) filter (Asahi Kasei Medical Co., Ltd. Tokyo, Japan). Two independent batches of 263K MF were used. WB1 analysis of samples before and after filtration was performed to determine the removal of PrP^{Sc} under the different conditions. Non-sonicated 263K MF (from the same batch of 263K MF) was also filtered as a control.

2.4. Hamster bioassay to determine the infectious titer of 263K scrapie stocks

Three- to four-week-old female specific pathogen-free (SPF) Syrian hamsters were used in these experiments. Serial 10-fold dilutions of each sample or positive control were prepared in PBS. Six hamsters per sample dilution were inoculated intra-cerebrally with 0.02 ml per animal. The inoculated animals were monitored daily for general health, and weekly for clinical evidence of scrapie. Animals were euthanized once advanced signs of scrapie were evident, or at the end of the assay period (200 days). The brain was removed from each hamster following euthanasia: one half was fixed for histopathology and the other half was stored frozen at -70 °C for further analysis if required. For histopathological analysis, sections taken at four standard coronal levels, to cover the nine areas of the brain which are recognized to be mostly infected by the scrapie agent, were stained with hematoxylin and eosin, and scored for the presence or absence of scrapie lesions [15]. Histopathological analysis was performed on samples from around the clinical end-point of the titration assays, to confirm the clinical results. Hamsters that died during the

course of the study for reasons other than scrapie infection were not included in the final calculation of infectious titers. Infectious titers were expressed as a 50% lethal dose (LD₅₀) according to the method of Kärber [16].

Samples taken before and after filtration during the P-15N/antithrombin (AT; previously named antithrombin-III) study were tested for the presence of scrapie infectivity using a qualitative hamster bioassay. Syrian hamsters were inoculated with undiluted samples only, as described above, except that only three animals were used per sample.

2.5. Evaluation of PrP^{Sc} removal in the presence of plasma preparations

To investigate whether differences in how the scrapie spike material was prepared influenced our evaluation of prion removal, two different spiked preparations were compared using the manufacturing process for preparing AT (Neuart[®], Benesis Corp., Osaka, Japan). Samples taken during the actual manufacturing process, immediately before the Planova step, were spiked with 263K MF treated with 0.1% (w/v) sarkosyl for 30 min at room temperature, or with 220 nm-filtered "super-sonicated" 263K MF. The spiked AT materials were then passed through a P-15N filter. The influence of different filtration conditions on the removal of PrP^{Sc} was compared for the same spike preparations, and for different spike preparations, using heat/PEG-treated intravenous immunoglobulin (IVIG) (Venoglobulin-IH, Benesis Corp.) and haptoglobin (Haptoglobin Injection-Yoshitomi, Benesis Corp.). Samples taken during the actual manufacturing process, immediately before the Planova step, were spiked with: 220 nm-filtered "super-sonicated" 263K MF (IVIG/P-35N and haptoglobin/P-35N); 263K MF ultracentrifuged at 141,000 × g for 60 min at 4 °C, resuspended in buffer equivalent to the starting material without protein, "super-sonicated" and 220 nm-filtered (IVIG/P-20N); or 263K MF treated with 0.3% (v/v) TNBP/1% (v/v) Tween 80 for 6 h at 30 °C ("SD treatment"), ultracentrifuged at 141,000 × g for 60 min at 4 °C, resuspended in saline, "super-sonicated", and 220 nm-filtered (haptoglobin/P-20N). The spiked material was then passed through either a P-35N filter or a P-20N filter (19 ± 2 nm). Although not part of the manufacturing process for haptoglobin, the SD treatment was included for the spiked preparation in an effort to reduce the clogging of the filter that occurs following the addition of a prion spike. Filtration processes for the thrombin preparation (Thrombin-Yoshitomi, Benesis Corp.) were also investigated. For thrombin, a sample taken during the actual manufacturing process immediately before the Planova step was spiked with 263K MF subjected to "SD treatment" followed by ultracentrifugation at 141,000 × g for 60 min at 4 °C, resuspended in the starting material, "super-sonicated" and 220 nm-filtered, and the spiked material then passed through a P-15N filter.

The experimental conditions used in the prion removal studies were designed to mimic the conditions used during the actual manufacturing process for the relevant product. For all processes, samples were analyzed by WB. The log₁₀ reduction factor (LRF) for PrP^{Sc} was calculated for each

filtration run, by comparing the total amount of PrP^{Sc} present in samples before and after filtration. All studies involving the use of WB1 and 2, and the quantitative bioassays, were performed in facilities in compliance with current GLP regulations. Studies involving the determination of average particle size in normal MF preparations, the use of WB3, and the qualitative bioassay, were performed as non-GLP studies.

3. Results

3.1. Influence of MF preparation method on particle size distribution

Ideally, to represent a "worst case" challenge for a filter, the smallest form of prion protein, or infectious agent, should be used. Studies to investigate the optimum method for preparing the prion spike material were therefore performed. In these studies, changes in the average particle size in normal MF were investigated, as 263K-infected brain material could not be handled within our facility. Although prion particles in MF derived from 263K-infected brain material were not investigated directly, we tried to optimize the design of our experiments by minimizing the size of particles in normal MF, as particle size may influence filtration performance (both with respect to filter blockage, and removal of PrP^{Sc}). The results are shown in Figs. 1 and 2.

Treatment of normal MF with sarkosyl or lysolecithin reduced the average size of particles to approximately 100 nm, when 0.1% or higher concentrations of the detergents were used. However, below that concentration, the particle size did not change significantly, with the exception of 0.01% lysolecithin which reduced the average particle size to approximately 300 nm (Fig. 1A,B). Treatment with Triton X-100 did not result in a significant change in particle size, even at 1% (Fig. 1C). Treatment with 0.3% TNBP or 1% Tween 80 alone was not able to reduce the particle size below 200 nm. However, when combined, one of the conditions generally used for viral inactivation ("SD treatment"), 0.3% TNBP and 1% Tween 80 reduced the average particle size to below 200 nm (Fig. 1D). These results suggest that the reduction in average particle size in normal MF depends on the choice of detergent(s), and the concentration and combination of detergent(s) used.

We also studied the effect of "super-sonication" on the particle size in normal MF. The results showed that "super-sonication" could reduce the average particle size to a very fine level in a short time, without the need to change the composition of the normal MF material (Fig. 2A). Since "super-sonication" is a temporary physical procedure, reversal of the particle size reduction may possibly occur. To exclude this possibility during the experiments, we conducted a stability study on the particle size in normal MF after "super-sonication". There was no significant change in the particle size up to 24 h after "super-sonication", with the size remaining at approximately 100 nm (Fig. 2B).

The results showed that the particle size of normal MF preparations could be reduced significantly by treatment




Fig. 1. Change of particle size in normal MF following treatment with various detergents. To normal MF, sarkosyl (A), lysolecithin (B), or Triton X-100 (C) was added to a final concentration of 1%, 0.1%, 0.01%, and 0.001%, respectively. The change in the average particle size was then monitored at room temperature for 90 min. In addition, TNBP or Tween 80 was added to normal MF to a final concentration of 0.3% and 1%, respectively, either alone, or in combination ("SD treatment"). The change in the average particle size was then monitored at 37 °C for 6 h (D).

with 0.1% sarkosyl, 0.1% lysolecithin, "SD treatment", or "super-sonication". The use of detergent or "SD treatment", in combination with "super-sonication", was also shown to effectively reduce the average particle size in normal MF preparations, to comparable levels to the individual treatments alone (data not shown). "Super-sonication" has an advantage over the other treatments in that it can minimize the change of composition of samples taken from the manufacturing process, as it does not require the addition of reagent(s) to the normal MF. For this reason, "super-sonication" is considered to be a useful approach for the treatment of 263K MF for process evaluation. "SD treatment", although slightly less effective,

is used in many manufacturing processes, and may therefore be useful alone, or in combination with "super-sonication", for the process evaluation of products whose manufacturing process includes an "SD treatment" step. These approaches, alone or in combination, may also be useful to prevent the clogging of filters that can occur during spiking studies.

3.2. Infectivity of PrP^{Sc} in 263K MF and influence of 263K MF preparation methods on infectivity

The effect of "super-sonication" and "SD treatment" on the infectivity of 263K MF was studied. Infectious titers of




Fig. 2. Change of particle size in normal MF following intense sonication ("super-sonication"). Normal MF in a test tube equipped with a resonance chip (20 kHz, 200 W) was sonicated for 1 min in an ice bath. After 1 min, the sonication step was repeated. The change in average particle size was monitored during 30 cycles of sonication (A). After 10 cycles of sonication ("super-sonication"), normal MF was held at room temperature for 24 h, and the change in particle size was monitored (B).

263K MF, "super-sonicated" 263K MF, and 263K MF subjected to "SD treatment", ultracentrifuged at $141,000 \times g$ for 60 min at 4 °C, resuspended with thrombin starting material, "super-sonicated", and 220 nm-filtered, were determined using a hamster bioassay. The results are summarized in Table 1.

The titers of two independent batches of 263K MF treated by "super-sonication" were 6.0 and 5.3 \log_{10} LD₅₀/ml, respectively. The titer of the "non-super-sonicated" 263K MF used to generate one of these stocks was 5.7 \log_{10} LD₅₀/ml. These results suggest that "super-sonication" does not influence the infectivity of 263K MF. The titer of the 263K MF subjected to "SD treatment", ultracentrifuged at $141,000 \times g$ for 60 min at 4 °C, resuspended with the thrombin starting material, "super-sonicated", and 220 nm-filtered, was 6.9 \log_{10} LD₅₀/ml, which was approximately 1 log higher than that of the corresponding stock treated by "super-sonication" alone. Whether this difference is significant is unclear. The process to generate the "SD-treated" spike materials included an ultracentrifugation step. We were therefore concerned about recovery of infectivity following centrifugation, as the particle size of 263K MF was highly reduced by the "SD treatment" step. However, these results suggested that the recovery of infectious particles following ultracentrifugation was satisfactory.

Although it is possible that use of a 200 day bioassay may under-estimate the infectious titer of the 263K MF stocks, the use of a relatively short duration bioassay is considered unlikely to affect the main conclusions drawn. At least the last two dilution groups tested showed no animals with evidence of scrapie infection in all four titrations, and only three animals in the study (one in each of three separate titrations) developed clinical symptoms necessitating euthanasia later than day 131 (euthanized on days 160, 183 and 183, respectively), suggesting the titers obtained for all the stocks are close to end-point (data not shown). In addition, as others have demonstrated that treatment with detergent, and exposure to treatments that result in inactivation of the scrapie agent, such as heat or NaOH, may result in extended incubation periods for clinical scrapie, if anything the results may under-estimate the relative titers of the treated stocks [17,18]. Therefore, the bioassay results support the conclusion that "super-sonication" of 263K MF stocks, with or without "SD treatment", does not appear to significantly reduce the infectious titer of the stock, and that these preparations are therefore suitable for use in prion clearance studies.

3.3. Removal of PrP^{Sc} by various filters

To determine whether "super-sonication" influenced the \log_{10} reduction observed for PrP^{Sc} following filtration under defined conditions, "super-sonicated" or "non-super-sonicated" stocks of 263K MF were diluted in PBS, and then filtered through 220 nm, 100 nm, P-75N, P-35N and P-15N filters. Samples were analyzed by WB. The results are summarized in Table 2. The use of "super-sonicated" 263K MF appeared to result in lower \log_{10} reduction values, supporting the idea that "super-sonication" of 263K MF produces a

more severe challenge for a filter step. An approximately 5-fold higher \log_{10} reduction factor was observed for "non-super-sonicated" stocks, for the 100 nm and P-75N filters, for both stocks tested. No significant loss of PrP^{Sc} was observed with either spiking material with 220 nm filtration, and no PrP^{Sc} was detected in the filtrates following P-35N and P-15N filtration.

Previously, we have observed some removal of PrP^{Sc} in some lots of "non-super-sonicated" 263K MF by 220 nm filtration. Strict control of the methodology used to generate the 263K MF stocks appeared to prevent this, suggesting that the method of preparing the 263K MF itself may influence the particle size distribution (data not shown).

3.4. Removal of PrP^{Sc} by Planova filters in the presence of plasma preparations

Removal of PrP^{Sc} by P-15N, P-20N, and P-35N filters was evaluated in the presence of a number of different plasma preparations, under conditions designed to mimic the relevant manufacturing process. The design of the experiments was similar to that of virus clearance studies. Samples were analyzed by WB, and the \log_{10} reduction factor (LRF) was calculated for each filter step. The results are shown in Table 3.

Under all the experimental conditions tested, PrP^{Sc} was not detected by WB after filtration through P-15N. The LRF values were ≥ 2.8 . In contrast, PrP^{Sc} was detected by WB in samples following filtration through P-20N and P-35N filters, in three out of the four processes tested, giving LRF values in the order of 2 logs. In one study, P-35N/haptoglobin, using "super-sonicated" 263K MF, PrP^{Sc} was not detected in the filtrate. However, the sensitivity of this study was low, giving a LRF of ≥ 1.4 , and therefore the robustness of this filtration process was not evaluated. In the initial studies (Table 2), PrP^{Sc} was not detected in the fractions after P-35N filtration of either "super-sonicated" or "non-super-sonicated" 263K MF in PBS, resulting in log reduction factors in the order of 3 logs. The variance in the results obtained for these filters could be due to a combination of factors, including how the scrapie spike material was prepared, the composition of the starting material, and the precise filtration conditions used.

3.5. Removal of prion infectivity by Planova filters in the presence of plasma preparations

P-15N filtration was shown in these studies to be able to remove PrP^{Sc} to levels below the detection limit of the WB assays used, regardless of the method used to prepare the spike material, the composition of the start material, or the filtration conditions. However, a bioassay study for samples generated in a P-15N/AT study using 220 nm-filtered "super-sonicated" 263K MF, demonstrated that infectivity was recovered following filtration, as clinical signs appeared in all hamsters inoculated with the filtrate, and analysis of hamster brain material confirmed the clinical results. PrP^{Sc} was detected in the brain homogenates from all clinically positive hamsters by WB, and scrapie-associated lesions were observed in all the

Table 4
Scrapie infectivity in samples generated during the P-15N/AT study

	Before filtration			Filtrate		
	Animal number			Animal number		
	1	2	3	1	2	3
Appearance of clinical signs (day euthanized)	87	87	87	94	143	105
PrP ^{Sc} in brain by WB3	Detected	Detected	Detected	Detected	Detected	Detected
Lesions by histopathology	+ve	+ve	+ve	+ve	+ve	+ve
Medulla (oblongata)	D,V,P	D,V,P	D,V,P	D,V,P	D,V,P	D,V,P
Cerebellum (cortex)	D	D,V,P	D,V,P	D,V,P	D,V,P	D,V,P
Midbrain	D,P	D,V,P	V,P	D,P	D,P	D,V,P
Hypothalamus	D,P	D,V,P	D,P	D,V,P	D,P	D,P
Thalamus	D,P	D,V,P	D,P	D,P	D,P	D,P
Hippocampus	NR	D,V	D	D	D,V,P	D,V
Paraterminal body	D,P	D,P	D,P	NR	D,V,P	P
Cerebral cortex (posterior midline)	D,P	D,P	D,P	D,P	D,V,P	D,V,P
Cerebral cortex (anterior midline)	D,P	D,V,P	D,V,P	D,V,P	D,V,P	D,V,P

Abbreviations used: +ve, scrapie positive; NR, no remarkable change; D, degeneration of nerve cell; V, vacuolation; P, proliferation of glial cell.

corresponding hamster brain material on histopathological observation (Table 4). Typical nerve lesions are shown in Fig. 3. Thus, P-15N filtration did not result in the complete removal of infectivity, for this process step.

4. Discussion

In this study, we have investigated the capacity of P-35N, P-20N and P-15N filters to remove the 263K scrapie prion protein, PrP^{Sc}, under the conditions used for the manufacture of four different plasma-derived products, using spike preparations designed to present a serious challenge to the filters.

Validation studies to evaluate the capacity of manufacturing processes to remove potential contaminants, including prions, are required for biological or biopharmaceutical products intended for human use. When designing these studies, a worst-case challenge should be used wherever possible, to minimize the risk of over-estimating the capacity of the process to remove such contaminants. Virus removal filters (or nanofilters) are designed to remove contaminants predominantly on the basis of size. The worst-case challenge for such steps should therefore be a preparation containing the smallest possible form of the infectious agent.

TSE clearance studies provide a particular challenge in that the nature of the infectious agent is still uncertain, and the forms of infectious agent present in plasma, and/or during the different stages of a manufacturing process, are not clearly understood. The causative agent of TSE diseases is believed to be strongly associated with, if not solely composed of, the disease-associated prion protein, PrP^{Sc}. Normal cellular PrP is a membrane-bound glycoprotein, which associates with membranes through a glycosylphosphatidylinositol (GPI) anchor. Prion infectivity is associated with heterogeneous particles, including membranes, liposomes and protein aggregates, so called prion rods. Therefore, methods which result in solubilization of membrane proteins, or dispersal of membrane fragments, vesicles and/or protein aggregates, may be expected to reduce the size of particles associated with prion infectivity.

Treatment of MF preparations derived from brains of uninfected (normal) hamsters with either detergent (0.1% lyssolecithin or 0.1% sarkosyl) or extensive sonication ("super-sonication") resulted in a rapid reduction in the average particle size, to approximately 100 nm. SD treatment (1% Tween 80 and 0.3% TNBP for 6 h) also resulted in a reduction in particle size, although this was slower and less effective, reducing the average particle size to the order of 200 nm.




Fig. 3. Typical nerve lesions in the hippocampus of a hamster brain, taken from an animal inoculated with a P-15N-filtered sample (B), in comparison with the corresponding region from an uninfected animal (A). Arrows, vacuolation; Arrowheads, degeneration of nerve cells; scale bar = 50 μ m; HE staining used.

“Super-sonication” has the advantage that it is a physical disruption process, and does not alter the chemical composition of the spike material, thus minimizing changes to the start material used for nanofiltration. SD treatment is included in many manufacturing processes for plasma-derived products, and therefore, although not as effective as “super-sonication”, use of this treatment might be expected to result in a spike material more closely mimicking the form of infectious prion present in the relevant start material during the manufacturing process. Use of these treatments alone or in combination may therefore be useful in reducing the size of infectious particles present in TSE spike materials for prion clearance studies.

The effect of the above treatments was studied using normal MF, as the facility was unable to handle infectious TSE materials. Although some care should be taken in extrapolating these results to TSE-infected brain material, “super-sonication” of 263K MF preparations appeared to reduce the removal of PrP^{Sc} following filtration, while detergent-treated spike preparations have previously been shown to present a more significant challenge to nanofiltration steps than untreated preparations ([9,10] and own unpublished observations). Furthermore, “super-sonication”, with or without SD treatment, does not appear to reduce the level of infectivity present within the 263K MF, supporting the use of such preparations for prion clearance studies.

Using 263K MF treated with 0.1% sarkosyl, “super-sonication” or SD plus “super-sonication”, we investigated the prion removal capacity of P-15N, P-20N and P-35N filters in the manufacturing processes used for four different plasma products. The results obtained suggest that both the composition of the materials to be filtered and the prion load influences the removal of prions. PrP^{Sc} was recovered in the filtrate fraction from three out of the four processing steps performed for P-20N and P-35N. In contrast, under all conditions tested, P-15N filtration resulted in removal of PrP^{Sc} to below the limit of detection of the Western blot assays used. Thus, P-15N would appear to be a more robust method for the removal of prions, reproducibly giving LRF in the order of 3 logs, under the conditions tested. In practice, however, it is not feasible to incorporate P-15N filtration into the manufacturing process for all plasma derivatives. From the results shown in Table 2, it may also be possible to optimize processing conditions to allow effective removal of PrP^{Sc} using P-20N or P-35N filters.

WB assays were used to monitor the partitioning of PrP^{Sc} during the nanofiltration processes. WB assays are semi-quantitative and serve to provide an indication of the relative levels of PrP^{Sc} present in different samples. However, there are limitations to the sensitivity of available WB assays, and these assays provide only an indirect measure of infectivity. Therefore, to confirm that removal of PrP^{Sc} does reflect removal of infectivity, bioassays need to be performed.

Although PrP^{Sc} was not detected in any of the P-15N filtered samples by WB assay, infectivity was recovered in a filtrate fraction tested by bioassay for one process run. Foster also noted that infectivity was detected in a filtrate fraction after P-15N filtration ([8] reported as personal communication; data not shown). Thus, even with P-15N, depending on the

processing conditions, there may be incomplete removal of prion contaminants.

Although infectivity was detected in the filtrate fraction from the one process step studied, longer and more variable incubation periods were observed in the animals inoculated with the filtrate sample (Table 4), suggesting a lower prion titer following filtration. However, it was not possible to estimate the relative levels of prion infectivity present in the input and filtrate samples, as no data was available to correlate incubation periods and prion titers for this study. Based on the titers typically observed for 263K MF stocks, the bioassay used could theoretically detect reductions in prion infectivity in the order of 4 logs for this process step. Detection of infectivity in the filtrate fraction by bioassay is therefore not necessarily incompatible with the WB results obtained (LRF ≥ 2.8 logs), and may simply reflect a difference in sensitivity between the two assays used.

As discussed above, uncertainties about the nature of the infectious agent in plasma, and during the manufacturing process, raise concerns about the design and interpretation of prion clearance studies. No single spike preparation is likely to contain all potential forms of the infectious agent. Infectivity is associated with membranes and protein aggregates. In addition, it has recently been shown that the GPI anchor is not required for infectivity, suggesting that endogenous proteolytic release of PrP^{Sc} from cell surfaces may also contribute to the spread of the infectious agent *in vivo* [19,20]. Whether significant levels of infectivity in human plasma are associated with GPI-anchorless prion protein is not yet clear. These different forms of infectivity, with different biophysical properties, could show different partitioning properties through the same manufacturing process [7]. Furthermore, different forms of the agent may differ in their level of infectivity. For example, it was recently reported that particles in the order of 17–27 nm appeared to have the highest relative level of infectivity, in comparison to levels of PrP^{Sc} [21]. Therefore, a better understanding of the nature and forms of the infectious agent is essential to allow the design of more accurate models for prion clearance studies, and a more confident evaluation of the safety of manufacturing processes with respect to potential TSE contamination.

In summary, we used methods intended to reduce the size of particles present within MF preparations in an effort to present a worst-case (smallest) prion challenge during nanofiltration. Using such preparations, P-15N filtration consistently reduced the level of PrP^{Sc} to below the limits of detection of the Western blot assays used, suggesting that this process step is effective for the removal of prions. However, data from a single process step studied suggested that infectivity could be recovered following P-15N filtration, and thus even P-15N filtration may not result in complete removal of prions, at least when used under some conditions.

Acknowledgements

A part of this study was presented at the Planova workshop 2003 and 2006 held by Asahi Kasei. Asahi Kasei Medical Co., Ltd. kindly gave us permission to publish the entire study on

Planova filters. Some of the data presented in this study has been summarized in a recent review [22].

References

- [1] Health Protection Agency. Fourth case of variant CJD infection associated with blood transfusion. Press release, http://www.hpa.org.uk/hpa/news/articles/press_releases/2007/070118_vCJD.htm, 18 January, 2007.
- [2] Castilla J, Saá P, Soto C. Detection of prions in blood. *Nature medicine* 2005;11(9):982–5.
- [3] European Medicines Agency/The Committee for Medicinal Products for Human Use (CHMP)/Biotechnology Working Party. CHMP position statement on Creutzfeldt–Jakob disease and plasma-derived and urine-derived medicinal products. EMEA/CPMP/BWP/2879/02/rev 1. London, <http://www.emea.europa.eu/pdfs/human/press/pos/287902rev1.pdf>, 23 June, 2004.
- [4] The European Agency for the Evaluation of Medicinal Products/The Committee for Medicinal Products for Human Use (CHMP)/Biotechnology Working Party. Guideline on the investigation of manufacturing processes for plasma-derived medicinal products with regard to vCJD risk. CPMP/BWP/5136/03 London, <http://www.emea.europa.eu/pdfs/human/bwp/513603en.pdf>, 21 October, 2004.
- [5] Strengthening of quality and safety assurance of drugs and medical devices manufactured using components of human origin as raw materials. PFSB notification no.0209003 dated February 9, 2005; Japan: MHLW (in Japanese).
- [6] Stenland CJ, Lee DC, Brown P, Petteway Jr SR, Rubenstein R. Partitioning of human and sheep forms of the pathogenic prion protein during the purification of therapeutic proteins from human plasma. *Transfusion* 2002;42(11):1497–500.
- [7] Vey M, Baron H, Weimer T, Gröner A. Purity of spiking agent affects partitioning of prions in plasma protein purification. *Biologicals* 2002; 30(3):187–96.
- [8] Foster PR. Removal of TSE agents from blood products. *Vox Sang* 2004; 87(S2):7–10.
- [9] Tateishi J, Kitamoto T, Ishikawa G, Manabe S. Removal of causative agent of Creutzfeldt–Jakob disease (CJD) through membrane filtration method. *Membrane* 1993;18(6):357–62.
- [10] Tateishi J, Kitamoto T, Mohri S, Satoh S, Sato T, Shepherd A, et al. Scrapie removal using Planova® virus removal filters. *Biologicals* 2001;29(1): 17–25.
- [11] Van Holten WR, Autenrieth S, Boose JA, Hsieh WT, Dolan S. Removal of prion challenge from an immune globulin preparation by use of a size-exclusion filter. *Transfusion* 2002;42(8):999–1004.
- [12] Kimberlin RH, Walker CA. Characteristics of a short incubation model of scrapie in the golden hamster. *J Gen Virol* 1977;34(2):295–304.
- [13] Kascsak RJ, Rubenstein R, Merz PA, Tonna-DeMasi M, Fersko R, Carp RI, et al. Mouse polyclonal and monoclonal antibody to scrapie-associated fibril proteins. *J Virol* 1987;61(12):3688–93.
- [14] Lee DC, Stenland CJ, Hartwell RC, Ford EK, Cai K, Miller JLC, et al. Monitoring plasma processing steps with a sensitive Western blot assay for the detection of prion protein. *J Virol Methods* 2000; 84(1):77–89.
- [15] Fraser H, Dickinson AG. The sequential development of the brain lesions of scrapie in three strains of mice. *J Comp Pathol* 1968;78(3):301–11.
- [16] Kärber J. Beitrag zur kollektiven Behandlung pharmakologischer Reihenversuche. *Arch Exp Pathol Pharmacol* 1931;162:480–3.
- [17] Somerville RA, Carp RI. Altered scrapie infectivity estimates by titration and incubation period in the presence of detergents. *J Gen Virol* 1983; 64(9):2045–50.
- [18] Taylor DM, Fernie K. Exposure to autoclaving or sodium hydroxide extends the dose-response curve of the 263K strain of scrapie agent in hamsters. *J Gen Virol* 1996;77(4):811–3.
- [19] Lewis PA, Properzi F, Prodromidou K, Clarke AR, Collinge J, Jackson GS. Removal of the glycosylphosphatidylinositol anchor from PrP^{Sc} by cathepsin D does not reduce prion infectivity. *Biochem J* 2006; 395:443–8.
- [20] Trifilo MJ, Yajima T, Gu Y, Dalton N, Peterson KL, Race RE, et al. Prion-induced amyloid heart disease with high blood infectivity in transgenic mice. *Science* 2006;313(5783):94–7.
- [21] Silveira RJ, Raymond JG, Hughson GA, Race ER, Sim LV, Hayes FS, et al. The most infectious prion protein particles. *Nature* 2005;437(7056): 257–61.
- [22] Yunoki M, Urayama T, Ikuta K. Possible removal of prion agents from blood products during the manufacturing processes. *Future Virol* 2006; 1(5):659–74.

Effect of intraventricular infusion of anti-prion protein monoclonal antibodies on disease progression in prion-infected mice

Chang-Hyun Song,¹ Hidefumi Furuoka,² Chan-Lan Kim,^{1†}
Michiko Ogino,^{1‡} Akio Suzuki,¹ Rie Hasebe¹ and Motohiro Horiuchi¹

Correspondence

Motohiro Horiuchi
horiuchi@vetmed.hokudai.ac.jp

¹Laboratory of Prion Diseases, Graduate School of Veterinary Medicine, Hokkaido University, Kita 18, Nishi 9, Kita-ku, Sapporo 060-0818, Japan

²Department of Pathobiological Science, Obihiro University of Agriculture and Veterinary Medicine, Inada-cho, Obihiro 080-8555, Japan

It is well known that anti-prion protein (PrP) monoclonal antibodies (mAbs) inhibit abnormal isoform PrP (PrP^{Sc}) formation in cell culture. Additionally, passive immunization of anti-PrP mAbs protects the animals from prion infection via peripheral challenge when mAbs are administered simultaneously or soon after prion inoculation. Thus, anti-PrP mAbs are candidates for the treatment of prion diseases. However, the effects of mAbs on disease progression in the middle and late stages of the disease remain unclear. This study carried out intraventricular infusion of mAbs into prion-infected mice before and after clinical onset to assess their ability to delay disease progression. A 4-week infusion of anti-PrP mAbs initiated at 120 days post-inoculation (p.i.), which is just after clinical onset, reduced PrP^{Sc} levels to 70–80% of those found in mice treated with a negative-control mAb. Spongiform changes, microglial activation and astrogliosis in the hippocampus and thalamus appeared milder in mice treated with anti-PrP mAbs than in those treated with a negative-control mAb. Treatment with anti-PrP mAb prolonged the survival of mice infected with Chandler or Obihiro strain when infusion was initiated at 60 days p.i., at which point PrP^{Sc} is detectable in the brain. In contrast, infusion initiated after clinical onset prolonged the survival time by about 8% only in mice infected with the Chandler strain. Although the effects on survival varied for different prion strains, the anti-PrP mAb could partly prevent disease progression, even after clinical onset, suggesting immunotherapy as a candidate for treatment of prion diseases.

Received 9 November 2007

Accepted 28 February 2008

INTRODUCTION

Prion diseases, such as scrapie, bovine spongiform encephalopathy (BSE) and Creutzfeldt–Jakob disease (CJD), are fatal neurodegenerative disorders characterized by accumulation of a disease-specific, abnormal isoform of the prion protein (PrP^{Sc}) in the central nervous system (CNS), astrogliosis, neuronal vacuolation and neuronal cell death. The appearance of BSE and variant CJD (vCJD), possibly linked to consumption of food derived from BSE-infected cattle, has increased awareness of prion diseases, but at present there is no effective treatment available for prion diseases. Given that transformation of a normal

prion protein (PrP^C) to PrP^{Sc} is a central event in the pathogenesis of prion disease, compounds and/or strategies that inhibit PrP^{Sc} formation are of therapeutic interest.

Many compounds or strategies have been reported to inhibit PrP^{Sc} formation, including polyanions, glycosaminoglycans, phosphorothioate oligonucleotides, tetrapyrroles, polyene antibiotics, tricyclic compounds, PrP peptides, dominant-negative PrP, cysteine protease inhibitors, PrP immunization and small interfering RNAs (reviewed by Trevitt & Collinge, 2006). Most of these compounds and treatments antagonize PrP^{Sc} formation in cells persistently infected with prions. However, the anti-prion effects *in vivo* are not always consistent with those observed *in vitro*. Indeed, some of the compounds and treatments protect animals from experimental inoculation with prions or delay the onset of disease when administered before, simultaneously or soon after inoculation with prions via a peripheral route (Ehlers & Diringer, 1984; Farquhar & Dickinson, 1986; Ladogana *et al.*, 1992; Priola

[†]Present address: Foreign Animal Disease Division, Animal Disease Control Department, National Veterinary Research and Quarantine Service, 480 Anyang-6 dong, Manan-gu, Anyang 430-824, Republic of Korea.

[‡]Present address: Institute of Tropical Medicine, Nagasaki University, 1-12-4 Sakamoto, Nagasaki 852-8523, Japan.

et al., 2000). In addition, only a few compounds, such as amphotericin B, its derivative, MS-8209 and pentosan polysulfate (PPS), can prolong survival of mice infected with prions even when administered in the middle or late stage of prion infection via intracerebral inoculation (Demaimay *et al.*, 1997; Doh-ura *et al.*, 2004). Because intraventricular infusion of PPS at a late stage prolongs the incubation period of the disease in transgenic mice that overexpress PrP (Doh-ura *et al.*, 2004), clinical trials using PPS to treat human prion diseases are moving forward (Todd *et al.*, 2005). The current evidence suggests that PPS treatment of vCJD patients appears to have some beneficial effects, although the specificity of the effects still needs to be evaluated carefully (Rainov *et al.*, 2007).

Anti-PrP antibodies prevent direct interaction between PrP^C and PrP^{Sc} in a cell-free conversion reaction (Kaneko *et al.*, 1995; Horiuchi & Caughey, 1999). Subsequent reports have shown that anti-PrP antibodies prevent prion propagation in cells persistently infected with prion (Enari *et al.*, 2001; Peretz *et al.*, 2001; Gilch *et al.*, 2003; Kim *et al.*, 2004b; Perrier *et al.*, 2004; Feraudet *et al.*, 2005). The inhibitory effect of anti-PrP antibodies has also been demonstrated *in vivo*. Transgenic mice expressing monoclonal antibody (mAb) 6H4 were shown to be resistant to prion infection via the intraperitoneal route (Heppner *et al.*, 2001). Moreover, active immunization with recombinant PrP, synthetic PrP peptide or a DNA vaccine has been shown to delay the onset of the disease in mice following peripheral prion infection, although immunization was a prerequisite to obtain the prophylactic effect (Sigurdsson *et al.*, 2002; Schwarz *et al.*, 2003; Goñi *et al.*, 2005; Fernandez-Borges *et al.*, 2006). Passive immunization with anti-PrP antibodies was found to be effective in preventing prion infection via the peripheral route if antibodies were administered shortly after prion inoculation, but was not following intracerebral prion infection or if administered on or after clinical onset following intraperitoneal prion infection (White *et al.*, 2003). These results suggest that anti-PrP antibodies can protect against establishment of prion infection in peripheral tissues and thus may be useful for post-exposure prophylaxis. However, the therapeutic potential of anti-PrP antibodies, including whether or not anti-PrP antibodies antagonize prion propagation in the brain and can inhibit disease progression when applied after clinical onset, remains to be elucidated.

To evaluate the therapeutic effects of anti-PrP antibodies on prion diseases more precisely, we carried out intraventricular infusion of anti-PrP mAbs in mice that had been inoculated intracerebrally with prions. Here, we show that intraventricular infusion of anti-PrP mAbs reduced the level of accumulation of PrP^{Sc} and reduced spongiform changes and gliosis relative to negative controls. Furthermore, we observed prolongation of the incubation time in mice infected with the Chandler strain, even when infusion was initiated at the time of clinical onset of the disease.

METHODS

Antibodies. The following anti-PrP mAbs were used in this study: 106 (IgG2b), 110 (IgG2b), 31C6 (IgG1) and 44B1 (IgG2a). The mAbs 106, 110 and 31C6 recognized linear epitopes consisting of mouse PrP aa 88–90, 83–89 and 143–149, respectively, whereas mAb 44B1 recognized a discontinuous epitope within aa 155–231 (Kim *et al.*, 2004a). Anti-feline parvovirus mAb P2-284 (IgG1) was used as a negative control (Horiuchi *et al.*, 1997). The mAbs were dialysed for 3 days against PBS prior to intraventricular infusion. An Alexa Fluor 488 Protein Labelling kit (Molecular Probes) was used for fluorescent labelling of mAbs.

The following rabbit polyclonal antibodies were used as primary antibodies for immunohistochemistry: B103, which recognizes bovine PrP synthetic peptide aa 103–121 (Horiuchi *et al.*, 1995), anti-glial fibrillary acidic protein (GFAP; Dako) to visualize astrocytes and anti-Iba1 (Wako) to visualize microglia.

Mice and prion strains. All procedures for animal experiments were carried out according to protocols approved by the Institutional Committee for Animal Experiments. Mouse-adapted scrapie strains Obihiro and Chandler were used in this study. For intracerebral inoculation, 4-week-old female ICR mice were purchased from CLEA Japan. Twenty microlitres of 10% brain homogenate from mice infected with the Obihiro or Chandler strain was injected into the left hemisphere. Twelve-week-old female ICR mice were used to determine the distribution of mAbs and to analyse neuronal toxicity by anti-PrP mAbs.

Intraventricular infusion of mAbs using an osmotic pump. Alzet Mini-Osmotic Pumps, models 2001, 2002 and 2004 (DURECT), were used in this study. Filling of the osmotic pumps with antibody solution was carried out according to the manufacturer's instructions. The pre-filled pumps were then placed in PBS at 37 °C for 24 h. Mice were fitted with a stainless steel cannula supplied with the Alzet Brain Infusion kit (DURECT) and positioned according to stereotaxic coordinates into the left lateral ventricle of the brain (bregma – caudal 1.0 mm, lateral 1.0 mm with a depth of 3 mm below the dura). The osmotic pumps were subsequently implanted subcutaneously into the back and connected to the fitted cannula. All surgical procedures were performed under anaesthesia by intramuscular injection of xylazine (10 mg kg⁻¹) and ketamine (50 mg kg⁻¹). After surgery, cefotaxime (Chugai) was administered subcutaneously (40 mg kg⁻¹) and a gentamicin ointment (Schering-Plough) was pasted on the suture line for 3 days. All mice were housed individually during post-surgery observation periods. Mice that died within a few days of the operation were excluded from the statistical analysis.

Stereotaxic injection of mAbs. Mice were anaesthetized as described above and placed onto a stereotaxic apparatus (Narishige). A linear scalp incision was made and the skull was exposed. Bilateral burr holes were drilled to accommodate stereotaxic placement into the left and right hippocampus (bregma – caudal 2.0 mm, lateral 2.1 mm). Using a Hamilton syringe with a 31-gauge needle, 2 µl mAbs (2 mg ml⁻¹) were injected into the left and right hippocampus, respectively, at a depth of 2 mm below the dura. Injection was carried out over a period of 15 min.

Western blotting. Brains were sagittally hemi-sectioned and homogenized in 10% (w/v) TMS buffer [50 mM Tris/HCl (pH 7.5), 5 mM MgCl₂, 5% glucose]. To detect PrP^{Sc}, 200 µl brain homogenate was mixed with an equal volume of a detergent buffer [8% Zwittergent 3-14, 1% Sarkosyl, 100 mM NaCl, 50 mM Tris/HCl (pH 7.5)] and treated with collagenase (0.5 mg ml⁻¹) for 15 min at 37 °C. The samples were then digested with proteinase K (PK; Roche)

at $20 \mu\text{g ml}^{-1}$ for 30 min at 37°C . After terminating PK activity by adding Pefabloc (Roche) at 2 mM, samples were treated with $40 \mu\text{g DNase I ml}^{-1}$ for 5 min. A half volume of a mixture of 2-butanol and methanol (5:1) was added and the PrP^{Sc} was pelleted by centrifugation at 20000 g for 10 min at 20°C . The resulting pellet was dissolved in $1 \times$ SDS sample buffer [62.5 mM Tris/HCl (pH 6.8), 5% glycerol, 3 mM EDTA, 4% β -mercaptoethanol, 0.04% bromophenol blue, 5% SDS, 4 M urea] by boiling for 5 min. SDS-PAGE and Western blotting were carried out as described elsewhere (Uryu *et al.*, 2007).

Histopathology and immunohistochemistry. Mouse brains that had been infused with Alexa Fluor 488-conjugated mAbs were frozen in Tissue-Tek OCT compound (Sakura) and cryosections of 16–20 μm were prepared. The sections were dried and fixed with acetone for 10 min. Sections were mounted with Vectashield containing propidium iodide (PI; Vector Laboratories) and examined with a Nikon CI laser confocal microscope. The presence of infused mAb was also confirmed by direct detection as follows. The sections were reacted with EnVision⁺ System-labelled polymer conjugated to horseradish peroxidase (HRP) (Dako) for 45 min at 37°C and positive signals were detected using Simple Stain 3,3'-diaminobenzidine (DAB) solution (Nichirei). This was followed by counterstaining with Mayer's haematoxylin (Wako).

Dissected mouse brains were fixed in 10% formalin and embedded in paraffin. Sections (4 μm) were deparaffinized, rehydrated and subjected to haematoxylin and eosin (H&E) staining or immunohistochemistry. Antigen retrieval for immunohistochemistry was performed by hydrolytic autoclaving at 135°C for 20 min for detection of PrP^{Sc} and at 121°C for 10 min for GFAP and Iba1 (Furuoka *et al.*, 2005). The sections were treated with 3% H_2O_2 for 5 min, blocked with 10% normal goat serum for 30 min and then incubated for 45 min at 37°C with B103 at a dilution of 1:100, anti-GFAP at 1:5000 or anti-Iba1 at 1:100. After washing with PBS, the sections were reacted with EnVision⁺ System-labelled polymer-HRP for 45 min at 37°C . The sections were then rinsed and developed with Simple Stain DAB, followed by counterstaining with Mayer's haematoxylin.

Terminal uridine deoxynucleotidyl transferase dUTP nick end labeling (TUNEL) staining. Neuronal cell death was examined using an *In situ* Cell Death Detection kit (Roche). Four micrometer sections of paraffin embedded brain tissue were deparaffinized, rehydrated and incubated with $10 \mu\text{g PK ml}^{-1}$ for 10 min at 37°C . After washing with PBS, the sections were incubated with labelling mixture containing terminal deoxynucleotidyl transferase and digoxigenin-labelled dUTP conjugated FITC for 60 min at 37°C . The sections were counterstained with PI and examined with a CI laser confocal microscope.

RESULTS

Distribution of mAb in brain following intraventricular infusion

We first examined the distribution of mAb infused into the left lateral ventricle of mouse brain. Alexa Fluor 488-conjugated mAb 31C6 (anti-PrP mAb) or P2-284 (negative-control mAb) was infused into the left lateral ventricle and the distribution of mAb was examined at 7, 14, 24 and 34 days after the initiation of infusion. To examine the distribution of the mAbs, brain cryosections at the levels indicated in Fig. 1(a) were prepared. Fig. 1(c) shows the

detection of Alexa Fluor 488-conjugated mAb 31C6 in the hippocampus. Fluorescence was detected over the hippocampus (up to 14 days). Although the area of distribution gradually narrowed thereafter, mAbs were still detectable in the hippocampus at 20 days after the termination of infusion (i.e. at 34 days). In contrast, a very low-level fluorescent signal was detected in the hippocampus of a mouse infused with Alexa Fluor 488-conjugated mAb P2-284, even at 7 days after the initiation of infusion. These results suggested that the longer duration of mAb 31C6 in the hippocampus compared with the control mAb was due to binding of mAb 31C6 to PrP^C.

Fig. 1(d) summarizes the distribution of the anti-PrP mAb. The mAb was well distributed to areas surrounding the lateral and dorsal third ventricles, hippocampus and thalamus. The mAb was also detected in areas close to the ventral third ventricles. In addition, mAb was detected in regions of the medulla oblongata that face the fourth ventricle and the subarachnoid space, suggesting that the mAb infused into the lateral ventricle was distributed to many parts of brain, presumably via the flow of cerebrospinal fluid. Although the mAb was distributed to parts of the brain parenchyma, distribution of mAb into the cortex and cerebellum appeared to be less efficient. When observing sections under a microscope, we noticed that the mAb-infused hemisphere showed higher fluorescence intensity than that observed in the contralateral side (data not shown), suggesting that the distribution of mAb was not symmetrical. This tendency was confirmed by direct detection of Alexa Fluor 488-conjugated mAb 31C6 (Fig. 1b).

Effects of anti-PrP mAbs on PrP^{Sc} accumulation in the brain

Mice inoculated with Obihiro or Chandler strain reach the terminal stage of the disease at around 150 days post-inoculation (p.i.). Early clinical signs such as ataxia of hind limbs and changes in pelage and posture appear at around 120 days p.i. To evaluate the therapeutic potential of anti-PrP mAbs in a late stage of the disease, infusion of mAbs was started at 120 days p.i. and accumulation of PrP^{Sc} and neurohistopathological lesions were analysed.

Fig. 2(a) shows PrP^{Sc} accumulation in the brains of mice infected with the Obihiro strain at 30 days post-infusion (150 days p.i.). The mean PrP^{Sc} levels in mice treated with mAbs 110, 31C6 and 44B1 were 78, 69 and 77%, respectively, compared with the control (mAb P2-284; $n=2$). To determine whether the relative reduction in PrP^{Sc} levels was caused by acceleration of PrP^{Sc} degradation or deceleration of PrP^{Sc} accumulation, we analysed the kinetics of PrP^{Sc} accumulation during the period from 127 to 150 days p.i. (Fig. 2b). There was no difference in PrP^{Sc} levels in mice treated with anti-PrP mAbs compared with those treated with the negative-control mAb at 127 days p.i. (7 days after the initiation of infusion). However, PrP^{Sc} levels increased 2.3-fold in mice treated with the control




Fig. 1. Distribution of mAbs following intraventricular infusion. Alexa Fluor 488-conjugated mAb 31C6 or P2-284 was infused into the left lateral ventricle using an Alzet Mini-Osmotic Pump model 2002 (mAb concentration 0.5 mg ml^{-1} , pumping rate $0.5 \mu\text{l h}^{-1}$, duration 14 days, volume $200 \mu\text{l}$). (a) Levels of coronal section examined. Cryosections at the indicated levels were prepared. (b) Detection of mAbs by direct staining. A frozen section at level b was prepared from the brain of a mouse sacrificed at 5 days after starting infusion and the distribution of mAb was visualized by direct staining. Bar, $500 \mu\text{m}$. (c) Detection of mAbs in the hippocampus. mAbs conjugated with Alexa Fluor 488 were analysed by laser confocal microscopy. Bars, $200 \mu\text{m}$. (d) Distribution of mAb after infusion. The distribution of mAb at 7, 14, 24 and 34 days after starting infusion (green) was superimposed on the images taken from Paxinos & Franklin (2001).

mAb over the period 127–150 days p.i., whereas PrP^{Sc} levels increased only 1.6-, 1.3- and 1.3-fold in mice treated with mAbs 110, 31C6 and 44B1, respectively. These results

indicated that anti- PrP^{Sc} mAbs can reduce the rate of PrP^{Sc} accumulation in the brain, even when treatment is initiated at a late stage of the disease.




Fig. 2. Effects of anti-PrP mAbs on PrP^{Sc} accumulation and spongiform changes in mice infected with the Obihiro strain. mAbs were infused into the left lateral ventricle of mice inoculated with the Obihiro strain at 120 days p.i. using an Alzet Mini-Osmotic Pump model 2004 (mAb concentration 2 mg ml⁻¹, pumping rate 0.25 μ l h⁻¹, duration 28 days, volume 200 μ l). Mouse brains were cut sagittally along the midline. The left hemisphere (mAb-infused side) was used for the detection of PrP^{Sc} by Western blotting, whereas the right hemisphere (non-infused side) was fixed with 10% formalin for paraffin sections. (a) Accumulation of PrP^{Sc} at 150 days p.i. Samples from individual mice (50 μ g brain equivalent) were loaded in each lane and the intensities of PrP^{Sc} bands were quantified. The mean intensity for mice treated with the negative-control mAb (P2-284) was designated 100% and the graph shows relative PrP^{Sc} levels for mice treated with anti-PrP mAbs. (b) Kinetics of PrP^{Sc} accumulation. Mice were sacrificed at 127 and 150 days p.i. and the left hemisphere (mAb-infused side) was used for Western blotting. Samples from individual mice (50 μ g brain equivalent) were loaded in each lane and chemiluminescence intensities were quantified. The graph on the right shows the mean level of PrP^{Sc} at 150 days p.i. compared with the level at 127 days p.i. Samples at 150 days p.i. were the same as those in (a). (c) Spongiform changes at 150 days p.i. Paraffin sections were prepared from the contralateral hemisphere of the brain described in (a) and stained with H&E.

Effects of anti-PrP mAbs on neurodegeneration

Next, we investigated the effects of mAbs on neurodegeneration. To do this, the contralateral hemispheres of brains used in Fig. 2(a) (at 150 days p.i.) were examined histopathologically. Although mAbs were more readily detected in the infused side than in the contralateral side (Fig. 1), spongiform changes in the hippocampus and thalamus of mice treated with mAbs 110, 31C6 and 44B1 were nevertheless milder than those treated with the negative-control mAb (Fig. 2c).

Immunohistochemical examination also revealed that anti-PrP mAbs affected the progression of neuropathological lesions in mice infected with the Obihiro strain (Fig. 3). Consistent with the reduction in PrP^{Sc} levels by anti-PrP mAbs (Fig. 2a), PrP^{Sc} deposition in the hippocampus and thalamus of mice infused with mAbs 110 and 31C6 was milder than in the negative control. In addition, astrogliosis (as evaluated by GFAP staining) appeared to be reduced in mice treated with anti-PrP mAbs compared with the negative control. Microglial activation in the




Fig. 3. Effects of anti-PrP mAbs on PrP^{Sc} accumulation and gliosis in mice infected with the Obihiro strain. Intraventricular infusion of mAbs was carried out as described in Fig. 2 and brains collected at 150 days p.i. were used for analysis. The mice shown in this figure belonged to an independent experimental group (i.e. different from the experimental group shown in Fig. 2). Paraffin-embedded sections were stained with B103 antibodies to detect PrP^{Sc}, anti-GFAP antibodies to detect astrocytes and anti-Iba1 antibodies to detect microglia. Images of the hippocampus and thalamus are indicated. All images represent the mAb-infused side. Bars, 200 μ m.

hippocampus (as detected with anti-Iba1 antibodies) was also reduced in the presence of anti-PrP mAbs; in contrast, the effect was marginal in the thalamus.

To investigate the effects of anti-PrP mAbs on different prion strains, we carried out the same experiment using mice infected with the Chandler strain. Similar to what was observed for mice infected with the Obihiro strain, in mice infected with the Chandler strain, mAb 31C6 reduced spongiform changes and PrP^{Sc} deposition in the hippocampus and thalamus compared with the negative-control mAb (Fig. 4). However, the effect of anti-PrP mAb on gliosis appeared to differ for the two different prion strains. Anti-PrP mAbs apparently reduced astrogliosis in the hippocampus and thalamus of mice infected with the Obihiro strain (Fig. 3), but only a slight reduction in astrogliosis was observed for mice infected with the Chandler strain (Fig. 4). Moreover, although microglial activation in the thalamus of mice infected with the Obihiro strain was slightly reduced by treatment with anti-PrP mAbs, it was obviously reduced relative to controls by treatment with mAb 31C6 in mice infected with the Chandler strain (Fig. 4). However, microglial activation as a whole appeared to be moderate in mice infected with the Chandler strain compared with the Obihiro strain; thus, the difference observed could be due to a difference in the level of activation of the microglia between mice infected with the two prion strains.

Prolongation of survival time

To determine whether treatment with anti-PrP mAbs can prolong survival of prion-infected mice when administered at different stages in progression of the disease, infusion was started at a middle stage of infection (60 or 90 days p.i.) and after clinical onset (120 days p.i.). In mice infected with the Obihiro strain, infusion of mAb 31C6 initiated at 60 days p.i. prolonged survival by about 11 days compared with the negative control; however, no effect was observed when infusions were initiated at 90 or 120 days p.i. (Fig. 5 and Table 1). In contrast, for mice infected with the Chandler strain, prolongation of survival was observed in all three groups: infusion initiated at 60, 90 or 120 days p.i. prolonged survival by approximately 10, 13 or 12 days, respectively. Brain sections (H&E stained) of all mice were examined for possible causes of death other than prion disease. Of 96 mice tested, two had severe abscesses around the infused area and thus were excluded from the experimental group.

Changes in body weight were consistent with prolonged survival times. For experimental groups in which survival was prolonged by infusion with mAb 31C6, the decrease in body weight observed in control groups was delayed by about 1 or 2 weeks (Fig. 6). In contrast, no difference was observed for mice infected with the Obihiro strain when mAb infusion was started at 90 or 120 days p.i.




Fig. 4. Effects of anti-PrP mAbs on neuropathological changes in mice infected with the Chandler strain. Intraventricular infusion of mAbs was carried out as described in Fig. 2 using mice inoculated with the Chandler strain and brains collected at 150 days p.i. were used for analysis. The hippocampus and thalamus from mAb-infused hemispheres are shown. Bars, 100 μ m.

Neuronal toxicity of mAbs

As it has been reported that an anti-PrP mAb recognizing aa 95–105 of murine PrP can induce apoptosis in hippocampal neurons (Solfrosi *et al.*, 2004), we assessed the neurotoxicity of the mAbs used in this study. First, mAbs were infused into the lateral ventricle for 7 days using an Alzet Mini-Osmotic Pump model 2001 (mAb concentration 1 mg ml⁻¹, pumping rate 1 μ l h⁻¹, duration 7 days, volume 200 μ l); however, no difference was observed between mice treated with anti-PrP mAbs and those treated with the negative-control mAb (data not shown). To assess neurotoxicity directly, we next stereotaxically injected anti-PrP mAbs and the control mAb into the left and right hippocampus, respectively. The distribution of mAb in the hippocampus was confirmed by injecting Alexa Fluor 488-conjugated mAb 31C6 (Fig. 7a). Although mAb was well-distributed throughout the entire hippocampus on the injected side, TUNEL-positive cells were only detected in a limited area of the pyramidal layer and this was observed even in the right side (the side injected with the control mAb P2-284). Indeed, the

TUNEL-positive cells were close to the injection site, suggesting that the TUNEL-positive cells resulted from the trauma of mAb injection. It was interesting that mAbs 106 and 110 recognizing the region adjacent to aa 95–105 did not induce apparent neuronal death.

DISCUSSION

In this study, we investigated the effects of anti-PrP mAbs on progression of prion disease, focusing on treatment during late stages of infection. We showed that anti-PrP mAbs antagonized PrP^{Sc} formation in the brain when intraventricular administration was initiated at the time of clinical onset (Figs 2 and 3). The effect of anti-PrP mAbs appeared to be mainly due to deceleration of PrP^{Sc} formation rather than active degradation of PrP^{Sc}. Several reports have suggested that binding of anti-PrP antibodies to the first α -helical domain of PrP^C (aa 143–155), which is proposed to be important for the PrP^C-PrP^{Sc} interaction (Morrissey & Shakhnovich, 1999; Speare *et al.*, 2003), prevents PrP^{Sc} formation by inhibiting the direct inter-




Fig. 5. Intraventricular infusion of anti-PrP mAb prolongs survival. Intraventricular infusion of mAbs into mice inoculated with the Obihiro or Chandler strain was initiated at 60, 90 or 120 days p.i. using an Alzet Mini-Osmotic Pump model 2002 (antibody concentration 2 mg ml^{-1} , pumping rate $0.5 \mu\text{l h}^{-1}$, duration 14 days, volume $200 \mu\text{l}$). Mice were observed until they reached the terminal stage of the disease. The graphs show survival curves, and survival times (means \pm SD) in days are shown in Table 1, together with the numbers of mice in each group. ○, Mice treated with mAb P2-284; ■, mice treated with mAb 31C6. The presence of PrP^{Sc} was confirmed by Western blotting in all experimental-group mice.

action between PrP^C and PrP^{Sc} (Enari *et al.*, 2001; Peretz *et al.*, 2001). It has also been suggested that a perturbation of the usual PrP^C trafficking by binding of the antibody to PrP^C on the cell surface, e.g. sequestration of PrP^C on the cell membrane, may be one of the mechanisms of inhibition (Kim *et al.*, 2004b; Feraudet *et al.*, 2005). Consistent with our previous observations (Kim *et al.*, 2004b), mAbs directed against the C-terminal domain (mAb 44B1) and the octapeptide repeat in the N-terminal region (mAb 110), as well as one directed against the first α -helix (mAb 31C6), antagonized PrP^{Sc} formation in the mouse brain (Fig. 2). Indeed, anti-PrP mAb infused into the lateral ventricle was still detectable in the hippocampus at 20 days after the termination of infusion, whereas only a low level of the negative-control mAb was detected in the same region, even during infusion (Fig. 1). These results suggest that the antibody-PrP^C complex remains in the brain parenchyma and therefore that sequestration of PrP^C

by the antibody is implicated in the inhibition of PrP^{Sc} formation *in vivo*.

Intraventricular infusion of anti-PrP mAbs at a late stage of infection (initiated at 120 days p.i.) reduced levels not only of PrP^{Sc} accumulation but also of microglial activation, astrogliosis and spongiform changes. Comparison of neurohistopathological changes observed at 127 versus 150 days p.i. in mice treated with anti-PrP mAbs and the negative-control mAb revealed an apparent reduction in gliosis observed at 150 days p.i., which may be due to a slowdown in the progression of gliosis (data not shown). Although the severity of microglial activation and astrogliosis differed in animals infected with the two different prion strains, the reduction observed was in accordance with the mAb distribution, and the levels of microglial activation and astrogliosis in the hippocampus and thalamus of mice infused with anti-PrP mAbs appeared

Table 1. Effect of intraventricular infusion of anti-PrP mAbs on survival of mice infected with the Obihiro or Chandler strain

Initiation of mAb infusion (days p.i.)	Survival time of mice [mean \pm SD (days)]			
	Obihiro strain		Chandler strain	
	P2-284 (n)	31C6 (n)	P2-284 (n)	31C6 (n)
60	153.4 \pm 9.0 (8)	163.5 \pm 8.1* (10)	150.7 \pm 10.2 (7)	161.0 \pm 8.3* (6)
90	152.8 \pm 4.3 (6)	153.3 \pm 3.5 (7)	151.7 \pm 9.8 (10)	165.0 \pm 10.9* (9)
120	151.4 \pm 9.4 (8)	157.4 \pm 7.0 (8)	152.9 \pm 7.4 (7)	164.9 \pm 9.3* (8)

*Statistically significant difference based on Student's *t*-test ($P < 0.05$).




Fig. 6. Changes in body weight. After the initiation of mAb infusion, mice were weighed weekly up to the terminal stage of the disease. The groups of mice used in Fig. 5 were used to monitor body weight. \circ , Mice treated with mAb P2-284; \blacksquare , mice treated with mAb 31C6.

to be milder than those observed in mice infused with the negative-control mAb. In contrast, no apparent reduction in microglial activation or astrogliosis by anti-PrP mAb was observed in the lateral cortex, where delivery of mAbs appeared to be inefficient (data not shown). It has been reported that the process of conversion of PrP^C to PrP^{Sc} on neurons rather than extracellular deposition of PrP^{Sc} is involved in neuronal degeneration (Brandner *et al.*, 1996; Mallucci *et al.*, 2003; Chesebro *et al.*, 2005). Although the mechanism by which PrP^{Sc} formation provokes microglial activation and astrogliosis remains to be elucidated, these results imply that arresting conversion of PrP^C to PrP^{Sc} via mAb infusion may contribute, at least to some extent, to the observed reduction in microglial activation and astrogliosis.

Previous results have shown that passive immunization with anti-PrP mAb via intraperitoneal injection does not have a protective effect after invasion of prion into the CNS or inoculation of prion via the intracerebral route (White *et al.*, 2003). In contrast, intraventricular infusion of anti-PrP mAb prolonged survival when mAb was infused at the time that PrP^{Sc} became detectable in the CNS (e.g. at 60 days p.i.). The difference seems to be explained by inadequate transfer of anti-PrP mAbs into the CNS across the blood-brain barrier when mAbs are administered peripherally. Several compounds, including amphotericin B, PPS, porphyrin derivatives and GN8, have been reported to prolong the survival of mice infected with prion when administered at the middle or late stage of infection, but the animals were still prior to clinical onset (Demaimay *et al.*, 1997; Doh-ura *et al.*, 2004; Kocisko *et al.*, 2006; Kuwata

et al., 2007). To the best of our knowledge, there has been only one report of a treatment that prolongs survival of animals already in the clinical phase. Specifically, intraperitoneal administration of MS-8209 was shown to prolong survival of mice infected with the C506M3 strain when treatment was carried out at the time of the appearance of neurological symptoms (Demaimay *et al.*, 1997). Human prion diseases are usually detected after clinical onset and thus the availability of treatments that are effective even after symptoms have begun to appear is highly important. Therefore, it is of interest that intraventricular infusion of anti-PrP mAb was effective for prolongation of survival, even when treatment was initiated after the appearance of early clinical signs (at 120 days p.i.) in mice infected with the Chandler strain. Although in this study mAb infusion for 14 days of duration achieved only 8% prolongation, the result should encourage further trials with mAbs that may be useful in the development of therapeutic treatment for prion diseases. For instance, continuing treatment over a longer duration, which may keep the effective concentration of mAbs in the brain higher over a longer period of time, may improve the effect on survival. In addition, anti-PrP mAb prolonged survival, despite the fact that the infused mAb was not evenly distributed in the brain but rather was primarily restricted to the hippocampus and thalamus. Thus, it is conceivable that improved delivery of mAb might enhance the effects of anti-PrP mAb on survival. Fab and single-chain antibody fragments have also been shown to inhibit PrP^{Sc} formation (Peretz *et al.*, 2001; Donofrio *et al.*, 2005), and the smaller size of these fragments may be beneficial for efficient delivery in tissues.




Fig. 7. Neuronal toxicity of anti-PrP mAbs. Anti-PrP mAbs (106, 110, 31C6 or 44B1) and the negative-control mAb P2-284 were injected into the left and right hippocampus, respectively, using stereotaxic apparatus. Seventy-two hours after injection, brains were obtained and fixed in 10% formalin. Paraffin sections were subjected to TUNEL and H&E staining. (a) Distribution of mAb. Alexa Fluor 488-conjugated mAb 31C6 was injected into the hippocampus and the distribution was analysed by confocal laser microscopy. (b) Positive control. Coronal sections were pre-treated with DNase I and then stained using the TUNEL procedure. The pyramidal cell layers of the hippocampus are shown. (c) TUNEL- and H&E-stained samples. Low-magnification (top panels) and high-magnification micrographs (middle panels) of TUNEL-stained samples and corresponding H&E-stained samples (bottom panels) are shown. The mAbs injected are indicated above the panels. Three to six mice were examined for each mAb. Bars, 200 μ m.

Although mice infected with either the Obihiro or Chandler strain succumbed to the disease at around 150 days p.i., the effect of mAb infusion on survival differed when administered to mice challenged with different prion strains. For example, mAb infusion of mice infected with the Chandler strain was effective when the mAb was administered at any of the three time points tested (60, 90 and 120 days p.i.), whereas no prolongation was observed in mice infected with the Obihiro strain when mAb infusion was initiated at 90 or 120 days p.i. (Fig. 6). At present, we do not have a precise explanation for this but can speculate on what might explain the difference. First, microglial activation in mice infected with the Obihiro strain was more severe than that in mice infected with the Chandler strain (Figs 3 and 4). Similar to the mouse model for Alzheimer's disease (El Khoury *et al.*, 2007), microglial recruitment is expected to have a protective role in prion disease; however, activated microglia also have neurotoxic effects via production of cytokines, chemokines and reactive oxygen species (Bate *et al.*, 2001, 2002; Marella *et al.*, 2005). Thus, even when mitigated by anti-PrP mAb, the severe microglial activation in mice infected with Obihiro strain may be sufficient for

progression of the disease. Secondly, differences in the distribution of PrP^{Sc} may account for the differences in the effect of anti-PrP mAb in one prion strain versus the other. For instance, PrP^{Sc} accumulation in the hypothalamus of mice infected with the Obihiro strain was more severe than that in mice infected with the Chandler strain (data not shown). Moreover, PrP^{Sc} formation in the hypothalamus might not be inhibited efficiently due to the uneven distribution of mAb in the hypothalamus (Fig. 1). These results may explain in part the lack of prolongation in the Obihiro strain-infected mice infused with mAb at 90 or 120 days p.i.

Immunotherapy has been of interest in the treatment of Alzheimer's disease; however, the fact that immunization of β -amyloid peptide caused meningoencephalitis in some patients in clinical trials warns of the adverse effects of autoimmune reactions *in vivo* (Check, 2002; Nicoll *et al.*, 2003; Orgogozo *et al.*, 2003). Additionally, cross-linking of PrP^C by an anti-PrP mAb that recognizes a specific epitope (aa 95–105) provoked degeneration of hippocampal and cerebellar neurons (Solfrosi *et al.*, 2004). These adverse effects of antibodies on the CNS have prompted extreme

caution in the use of anti-PrP antibodies, in particular, their introduction into the CNS. However, passive immunization is less likely to initiate an autoimmune reaction (Schenk, 2002; Sadowski & Wisniewski, 2004). In this study, we observed no antibody-induced inflammation by intraventricular infusion. In addition, neuronal death in the hippocampus was not observed, even though mAbs 106 and 110, which recognize the region adjacent to aa 95–105, were injected directly into the hippocampus. Although the potential adverse effects, especially an inflammatory response, should be examined carefully, the fact that anti-PrP mAbs interfered with disease progression, even when administered after clinical onset, is particularly encouraging. Although the effect of anti-PrP mAb differed in prion strains, this implies that the immunotherapy might be effective in certain types of human prion disease, if not all. Therefore, the results of this study should promote further efforts to improve the effect of anti-PrP mAbs, such as the form of the antibody, the route of administration and an efficient way of delivering the antibodies.

ACKNOWLEDGEMENTS

This work was supported by the Regional New Consortium R&D Projects from the Ministry of Economy, Trade and Industry, a grant from The 21st Century COE Program (A-1) and a Grant-in-Aid for Science Research (A) (grant no. 18208026) from the Ministry of Education, Culture, Sports, Science and Technology of Japan. This work was also supported by a grant from the Ministry of Health, Labour and Welfare of Japan (grant no. 17270701). This work was also partly supported by a grant for Strategic Cooperation to Control Emerging and Re-emerging Infections and the Program of Founding Research Centers for Emerging and Re-emerging Infectious Diseases, from the Ministry of Education, Culture, Sports, Science and Technology, Japan.

REFERENCES

Bate, C., Reid, S. & Williams, A. (2001). Killing of prion-damaged neurones by microglia. *Neuroreport* **12**, 2589–2594.

Bate, C., Boshuizen, R. S., Langeveld, J. P. & Williams, A. (2002). Temporal and spatial relationship between the death of PrP^{Sc} damaged neurones and microglial activation. *Neuroreport* **13**, 1695–1700.

Brandner, S., Isenmann, S., Raeber, A., Fischer, M., Sailer, A., Kobayashi, Y., Marino, S., Weissmann, C. & Aguzzi, A. (1996). Normal host prion protein necessary for scrapie induced neurotoxicity. *Nature* **379**, 339–343.

Check, E. (2002). Nerve inflammation halts trial for Alzheimer's drug. *Nature* **415**, 462.

Chesebro, B., Race, R. & Kercher, L. (2005). Scrapie pathogenesis in brain and retina: effects of prion protein expression in neurons and astrocytes. *J Neurovirol* **11**, 476–480.

Demaimay, R., Adjou, K. T., Beringue, V., Demart, S., Lasmézas, C. I., Deslys, J. P., Seman, M. & Dormont, D. (1997). Late treatment with polyene antibiotics can prolong the survival time of scrapie infected animals. *J Virol* **71**, 9685–9689.

Doh-ura, K., Ishikawa, K., Murakami-Kubo, I., Sasaki, K., Mohri, S., Race, R. & Iwaki, T. (2004). Treatment of transmissible spongiform

encephalopathy by intraventricular drug infusion in animal models. *J Virol* **78**, 4999–5006.

Donofrio, G., Heppner, F. L., Polymenidou, M., Musahl, C. & Aguzzi, A. (2005). Paracrine inhibition of prion propagation by anti-PrP single-chain Fv miniantibodies. *J Virol* **79**, 8330–8338.

Ehlers, B. & Diringer, H. (1984). Dextran sulphate 500 delays and prevents mouse scrapie by impairment of agent replication in spleen. *J Gen Virol* **65**, 1325–1330.

El Khoury, J., Toft, M., Hickman, S. E., Means, T. K., Terada, K., Geula, C. & Luster, A. D. (2007). Ccr2 deficiency impairs microglial accumulation and accelerates progression of Alzheimer-like disease. *Nat Med* **13**, 432–438.

Enari, M., Flechsig, E. & Weissmann, C. (2001). Scrapie prion protein accumulation by scrapie-infected neuroblastoma cells abrogated by exposure to a prion protein antibody. *Proc Natl Acad Sci U S A* **98**, 9295–9299.

Farquhar, C. F. & Dickinson, A. G. (1986). Prolongation of scrapie incubation period by an injection of dextran sulphate 500 within the month before or after infection. *J Gen Virol* **67**, 463–473.

Feraudet, C., Morel, N., Simon, S., Volland, H., Frobert, Y., Creminon, C., Vilette, D., Lehmann, S. & Grassi, J. (2005). Screening of 145 anti-PrP monoclonal antibodies for their capacity to inhibit PrP^{Sc} replication in infected cells. *J Biol Chem* **280**, 11247–11258.

Fernandez-Borges, N., Brun, A., Whitton, J. L., Parra, B., Diaz-San Segundo, F., Salguero, F. J., Torres, J. M. & Rodriguez, F. (2006). DNA vaccination can break immunological tolerance to PrP in wild-type mice and attenuates prion disease after intracerebral challenge. *J Virol* **80**, 9970–9976.

Furuoka, H., Yabuzoe, A., Horiuchi, M., Tagawa, Y., Yokoyama, T., Yamakawa, Y., Shinagawa, M. & Sata, T. (2005). Effective antigen-retrieval method for immunohistochemical detection of abnormal isoform of prion proteins in animals. *Acta Neuropathol* **109**, 263–271.

Gilch, S., Wopfner, F., Renner-Müller, I., Kremmer, E., Bauer, C., Wolf, E., Brem, G., Groschup, M. H. & Schatzl, H. M. (2003). Polyclonal anti-PrP auto-antibodies induced with dimeric PrP interfere efficiently with PrP^{Sc} propagation in prion infected cells. *J Biol Chem* **278**, 18524–18531.

Goñi, F., Knudsen, E., Schreiber, F., Scholtzova, H., Pankiewicz, J., Carp, R., Meeker, H. C., Rubenstein, R., Brown, D. R. & other authors (2005). Mucosal vaccination delays or prevents prion infection via an oral route. *Neuroscience* **133**, 413–421.

Heppner, F. L., Musahl, C., Arrighi, I., Klein, M. A., Rüllicke, T., Oesch, B., Zinkernagel, R. M., Kalinke, U. & Aguzzi, A. (2001). Prevention of scrapie pathogenesis by transgenic expression of anti-prion protein antibodies. *Science* **294**, 178–182.

Horiuchi, M. & Caughey, B. (1999). Specific binding of normal prion protein to the scrapie form via a localized domain initiates its conversion to the protease resistant state. *EMBO J* **18**, 3193–3203.

Horiuchi, M., Yamazaki, N., Ikeda, T., Ishiguro, N. & Shinagawa, M. (1995). A cellular form of prion protein (PrP^C) exists in many non-neuronal tissues of sheep. *J Gen Virol* **76**, 2583–2587.

Horiuchi, M., Mochizuki, M., Ishiguro, N., Nagasawa, H. & Shinagawa, M. (1997). Epitope mapping of a monoclonal antibody specific to feline panleukopenia virus and mink enteritis virus. *J Vet Med Sci* **59**, 133–136.

Kaneko, K., Peretz, D., Pan, K. M., Blochberger, T. C., Wille, H., Gabizon, R., Griffith, O. H., Cohen, F. E., Baldwin, M. A. & Prusiner, S. B. (1995). Prion protein (PrP) synthetic peptides induce cellular PrP to acquire properties of the scrapie isoform. *Proc Natl Acad Sci U S A* **92**, 11160–11164.

Kim, C. L., Umetani, A., Matsui, T., Ishiguro, N., Shinagawa, M. & Horiuchi, M. (2004a). Antigenic characterization of an abnormal

- isoform of prion protein using a new diverse panel of monoclonal antibodies. *Virology* 320, 40–51.
- Kim, C. L., Karino, A., Ishiguro, N., Shinagawa, M., Sato, M. & Horiuchi, M. (2004b). Cell-surface retention of PrP^C by anti-PrP antibody prevents protease-resistant PrP formation. *J Gen Virol* 85, 3473–3482.
- Kocisko, D. A., Caughey, W. S., Race, R. E., Roper, G., Caughey, B. & Morrey, J. D. (2006). A porphyrin increases survival time of mice after intracerebral prion infection. *Antimicrob Agents Chemother* 50, 759–761.
- Kuwata, K., Nishida, N., Matsumoto, T., Kamatari, Y. O., Hosokawa-Muto, J., Kodama, K., Nakamura, H. K., Kimura, K., Kawasaki, M. & other authors (2007). Hot spots in prion protein for pathogenic conversion. *Proc Natl Acad Sci U S A* 104, 11921–11926.
- Ladogana, A., Casaccia, P., Ingrassio, L., Cibati, M., Salvatore, M., Xi, Y. G., Masullo, C. & Pocchiarri, M. (1992). Sulphate polyanions prolong the incubation period of scrapie infected hamsters. *J Gen Virol* 73, 661–665.
- Mallucci, G., Dickinson, A., Linehan, J., Klöhn, P. C., Brandner, S. & Collinge, J. (2003). Depleting neuronal PrP in prion infection prevents disease and reverses spongiosis. *Science* 302, 871–874.
- Marella, M., Gaggioli, C., Batoz, M., Deckert, M., Tartare-Deckert, S. & Chabry, J. (2005). Pathological prion protein exposure switches on neuronal mitogen activated protein kinase pathway resulting in microglia recruitment. *J Biol Chem* 280, 1529–1534.
- Morrissey, M. P. & Shakhnovich, E. I. (1999). Evidence for the role of PrP^C helix 1 in the hydrophilic seeding of prion aggregates. *Proc Natl Acad Sci U S A* 96, 11293–11298.
- Nicoll, J. A., Wilkinson, D., Holmes, C., Steart, P., Markham, H. & Weller, R. O. (2003). Neuropathology of human Alzheimer disease after immunization with amyloid- β peptide: a case report. *Nat Med* 9, 448–452.
- Orgogozo, J. M., Gilman, S., Dartigues, J. F., Laurent, B., Puel, M., Kirby, L. C., Jouanny, P., Dubois, B., Eisner, L. & other authors (2003). Subacute meningoencephalitis in a subset of patients with AD after A β 2 immunization. *Neurology* 61, 46–54.
- Paxinos, G. & Franklin, K. B. J. (2001). *The Mouse Brain in Stereotaxic Coordinates*, 2nd edn. San Diego: Academic Press.
- Peretz, D., Williamson, R. A., Kaneko, K., Vergara, J., Leclerc, E., Schmitt-Ulrich, G., Mehlhorn, I. R., Legname, G., Wormald, M. R. & other authors (2001). Antibodies inhibit prion propagation and clear cell cultures of prion infectivity. *Nature* 412, 739–743.
- Perrier, V., Solassol, J., Crozet, C., Frobert, Y., Mourton-Gilles, C., Grassl, J. & Lehmann, S. (2004). Anti-PrP antibodies block PrP^{Sc} replication in prion-infected cell cultures by accelerating PrP^{Sc} degradation. *J Neurochem* 89, 454–463.
- Priola, S. A., Raines, A. & Caughey, W. S. (2000). Porphyrin and phthalocyanine antiscrapie compounds. *Science* 287, 1503–1506.
- Rainov, N. G., Tsuboi, Y., Krolak-Salmon, P., Vighetto, A. & Doh-Ura, K. (2007). Experimental treatments for human transmissible spongiform encephalopathies: is there a role for pentosan polysulfate? *Expert Opin Biol Ther* 7, 713–726.
- Sadowski, M. & Wisniewski, T. (2004). Vaccines for conformational disorders. *Expert Rev Vaccines* 3, 279–290.
- Schenk, D. (2002). Amyloid β immunotherapy for Alzheimer's disease: the end of the beginning. *Nat Rev Neurosci* 3, 824–828.
- Schwarz, A., Krätke, O., Burwinkel, M., Riemer, C., Schultz, J., Henklein, P., Bammé, T. & Baier, M. (2003). Immunisation with a synthetic prion protein derived peptide prolongs survival times of mice orally exposed to the scrapie agent. *Neurosci Lett* 350, 187–189.
- Sigurdsson, E. M., Brown, D. R., Daniels, M., Kascsak, R. J., Kascsak, R., Carp, R., Meeker, H. C., Frangione, B. & Wisniewski, T. (2002). Immunization delays the onset of prion disease in mice. *Am J Pathol* 161, 13–17.
- Solfrosi, L., Criado, J. R., McGavern, D. B., Wirz, S., Sánchez-Alavez, M., Sugama, S., DeGiorgio, L. A., Volpe, B. T., Wiseman, E. & other authors (2004). Cross-linking cellular prion protein triggers neuronal apoptosis in vivo. *Science* 303, 1514–1516.
- Speare, J. O., Rush, T. S., III, Bloom, M. E. & Caughey, B. (2003). The role of helix 1 aspartates and salt bridges in the stability and conversion of prion protein. *J Biol Chem* 278, 12522–12529.
- Todd, N. V., Morrow, J., Doh-ura, K., Dealler, S., O'Hare, S., Farling, P., Duddy, M. & Rainov, N. G. (2005). Cerebroventricular infusion of pentosan polysulphate in human variant Creutzfeldt-Jakob disease. *J Infect* 50, 394–396.
- Trevitt, C. R. & Collinge, J. (2006). A systematic review of prion therapeutics in experimental models. *Brain* 129, 2241–2265.
- Uryu, M., Karino, A., Kamihara, Y. & Horiuchi, M. (2007). Characterization of prion susceptibility in Neuro2a mouse neuroblastoma cell subclones. *Microbiol Immunol* 51, 661–667.
- White, A. R., Enever, P., Tayebi, M., Mushens, R., Linehan, J., Brandner, S., Anstee, D., Collinge, J. & Hawke, S. (2003). Monoclonal antibodies inhibit prion replication and delay the development of prion disease. *Nature* 422, 80–83.

ORIGINAL ARTICLE

Frequencies of *PRNP* Gene Polymorphisms in Vietnamese Dairy Cattle for Potential Association with BSE

Y. Muramatsu¹, Y. Sakemi¹, M. Horiuchi², T. Ogawa³, K. Suzuki⁴, M. Kanameda⁵, T. T. Hanh⁶ and Y. Tamura¹

¹ Department of Veterinary Public Health, School of Veterinary Medicine, Rakuno Gakuen University, Hokkaido, Japan

² Laboratory of Prion Diseases, Graduate School of Veterinary Medicine, Hokkaido University, Hokkaido, Japan

³ Department of Applied Science, School of Veterinary Nursing and Technology, Faculty of Veterinary Science, Nippon Veterinary and Life Science University, Tokyo, Japan

⁴ Facultad de Ciencias Veterinarias, Universidad Nacional de La Plata, Provincia de Buenos Aires, Argentina

⁵ Japan International Cooperation Agency (JICA), Tokyo, Japan

⁶ Department of Veterinary Hygiene, National Institute of Veterinary Research, Hanoi, Vietnam

Impacts

- We have investigated the frequencies of polymorphisms in the prion protein gene (*PRNP*) associated with bovine spongiform encephalopathy (BSE) susceptibility in Vietnamese dairy cattle for the first time.
- We have provided evidence that Vietnamese dairy cattle have a unique genetic background in the *PRNP*.
- We have provided the information on the genetic background in the *PRNP* of dairy cattle in Vietnam, where dairy farming is an emerging industry.

Keywords:

PRNP gene; BSE; cattle; Vietnam; indel polymorphisms

Correspondence:

Yasukazu Muramatsu, Department of Veterinary Public Health, School of Veterinary Medicine, Rakuno Gakuen University, 582 Bunkyo-dai-Midorimachi, Ebetsu, Hokkaido 069-8501, Japan. Tel.: +81 11 388 4800; Fax: +81 11 387 5890; E-mail: y-mrmt@rakuno.ac.jp

Received for publication November 14, 2007

doi: 10.1111/j.1863-2378.2008.01119.x

Summary

Since 2004, significant associations between bovine spongiform encephalopathy (BSE) susceptibility in cattle and frequencies of insertion/deletion (ins/del; indel) polymorphisms within the bovine prion protein gene (*PRNP*) have been reported. In this study, we investigated the frequencies of indel polymorphisms within two variable sites, a 23-bp indel polymorphism in the promoter region (23indel) and a 12-bp indel polymorphism in intron 1 region (12indel), in the *PRNP* in 206 Vietnamese dairy cattle and seven Japanese BSE-affected cattle. In Vietnamese dairy cattle, the frequency distributions of del allele and del/del genotypic polymorphisms in the 23indel site, which are thought to be associated with BSE susceptibility, were significantly higher, whereas the frequencies of del allelic and del/del genotypic polymorphisms in the 12indel site, which have been reported to confer BSE susceptibility, were significantly lower. We have provided evidence that Vietnamese dairy cattle have a unique genetic background in the *PRNP* gene in comparison with cattle or sires previously reported in other countries.

Introduction

In Vietnam, dairy farming is an emerging industry. For centuries, cattle have been reared for draught power, making manure and meat production. In the 1920s, dairy cattle breeding was first introduced to Vietnam. However, in the colonial period, dairy production was carried out by French residents. Nationwide expansion of dairy farm-

ing occurred in the 1970s. However, the overall production and consumption of dairy products remained very low because of war and the general poor socio-economic situation in the country (Luthi et al., 2006). Thus, until the government economic decentralization policy called 'Doi Moi' was initiated in 1986, there was almost no dairy industry in Vietnam. Since the 1980s, the dairy cow population has been increasing rapidly in both state-